Morgan Stanley analyst Ronald Kamdem maintained a Buy rating on Lineage, Inc. (LINE – Research Report) yesterday and set a price target of $80.00.
Ronald Kamdem has given his Buy rating due to a combination of factors that suggest potential future recovery and growth for Lineage, Inc. Despite the company’s recent underperformance compared to the broader REIT group, Kamdem sees the potential for demand recovery in 2025 as a significant opportunity. The valuation of Lineage, Inc. reflects low growth expectations, which could be advantageous if the anticipated demand recovery materializes.
Kamdem also highlights the potential for operational improvements and cash flow growth that may not be fully appreciated by the market. Additionally, there are several catalysts that could influence stock performance, including upcoming earnings results and management communications. The possibility of expense savings exceeding expectations further supports the Buy rating, as these factors could contribute to a more favorable financial outlook for Lineage, Inc.